NEW YORK (Reuters Health) Aug 20 –
In asthmatic patients, use of a leukotriene receptor antagonist (LTRA) protects against an almost doubling of the bronchial provocation dose required to produce a 20% fall in FEV1, according to a report in the July issue of Chest.
“Bronchial hyperresponsiveness or hyperreactivity is a noninvasive surrogate marker of airway inflammation, and is a reproducible method of assessing the efficacy of antiasthma therapy in the laboratory,” Dr. Brian J. Lipworth and Dr, Graeme P. Currie from the University of Dundee, Scotland, note.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!